Molgenbio Co., Ltd.

Molgenbio Co., Ltd. is a Korean biotechnology firm focused on the development of innovative, microorganism-derived small molecule drugs. Utilizing its proprietary Molecule through Gene (MtG) platform, the company employs synthetic biology techniques—such as microbial genome scanning, editing, and assembly—to modify and enhance naturally occurring compounds. This approach aims to create highly effective therapies for challenging medical conditions, including neurodegenerative diseases like Parkinson’s and Alzheimer’s, as well as cancer and hair loss.

The company is developing advanced therapeutic candidates, such as the FK506 derivative MG-TA205, which is designed to provide therapeutic benefits—including nerve regeneration and anti-inflammatory properties—while reducing the immunosuppressive side effects associated with the original molecule. By integrating synthetic biology with natural product chemistry, Molgenbio seeks to address unmet medical needs and improve treatment outcomes for patients suffering from chronic and incurable diseases. The company is actively working toward preclinical and clinical milestones, supported by a portfolio of domestic and international intellectual property.